Please assess the completion status of the following clinical trial:

Trial Title: BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe COPD~* At least one COPd exacerbation in previous year~Exclusion Criteria:~* Asthma, allergic rhinitis or other atopic disease~* Unstable concurrent disease:~* Evidence of heart failure

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BDP/FF (Type: EXPERIMENTAL): Beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/per metered dose inhaler
- Formoterol fumarate (Type: ACTIVE_COMPARATOR): Formoterol fumarate 12 µg per metered dose

Based on this trial design, predict the completion outcome and termination type (if applicable).